title: A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
abstract: BACKGROUND
  The aim was to evaluate the clinical performance of alpha(1)-antichymotrypsin prostate-specific antigen (PSA-ACT) for early diagnosis of prostate cancer (PCa) in a multicenter trial.
  
  
  METHODS
  Three hundred sixty-seven white men with PCa and 290 with benign prostatic hyperplasia (BPH) with tPSA concentrations between 2 and 20 microg/L were analyzed. The Elecsys system 2010 (Roche Diagnostics, Germany) was used for determination of total PSA (tPSA) and free PSA (fPSA). The PSA-ACT test was a prototype assay used on the ES system (Roche Diagnostics).
  
  
  RESULTS
  The median concentrations of tPSA (PCa: 8.43 microg/L vs. BPH: 6.60 microg/L) and PSA-ACT (8.30 microg/L vs. 6.46 microg/L) were significantly different, respectively. The median ratios of fPSA/tPSA (PCa: 12% vs. BPH: 16%) and PSA-ACT/tPSA (98% vs. 95%) were significantly different. Receiver operating characteristics (ROC) analysis for discrimination between PCa and BPH (tPSA between 2 and 20 microg/L) was performed with 252 matched pairs and showed that the area under the curve (AUC) of the ratio fPSA/tPSA (0.66) was significantly different from tPSA (0.50) and PSA-ACT (0.52). PSA-ACT alone or the ratio PSA-ACT/tPSA (0.56) were not significantly different from tPSA. For tPSA between 4 and 10 microg/L (n = 145 pairs), the AUC of the ratio fPSA/tPSA (0.65) was significantly higher than tPSA (0.50) and PSA-ACT (0.54). Significant differences between tPSA and PSA-ACT or PSA-ACT/tPSA (0.56) were not found.
  
  
  CONCLUSIONS
  The determination of PSA-ACT as well as the PSA-ACT/tPSA ratio did not improve the diagnostic impact in patients undergoing evaluation for PCa compared to fPSA/tPSA ratio.
authors.affiliation: Department of Urology, University Hospital Charité, Humboldt University, Berlin, Germany. Michael.Lein@charite.de
authors.forename: M
authors.initials: M
authors.lastname: Lein
authors.forename: K
authors.initials: K
authors.lastname: Jung
authors.forename: P
authors.initials: P
authors.lastname: Hammerer
authors.forename: M
authors.initials: M
authors.lastname: Graefen
authors.forename: A
authors.initials: A
authors.lastname: Semjonow
authors.forename: P
authors.initials: P
authors.lastname: Stieber
authors.forename: M
authors.initials: M
authors.lastname: Ossendorf
authors.forename: H J
authors.initials: HJ
authors.lastname: Luboldt
authors.forename: B
authors.initials: B
authors.lastname: Brux
authors.forename: C
authors.initials: C
authors.lastname: Stephan
authors.forename: D
authors.initials: D
authors.lastname: Schnorr
authors.forename: S A
authors.initials: SA
authors.lastname: Loening
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000276:immunology*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000276:immunology*; D011480:Protease Inhibitors / Q000097:blood*; D012372:ROC Curve; D018709:Statistics, Nonparametric; D000514:alpha 1-Antichymotrypsin / Q000097:blood*
chemical_list: D000911:Antibodies, Monoclonal; D011480:Protease Inhibitors; D000514:alpha 1-Antichymotrypsin; D017430:Prostate-Specific Antigen